Abstract
Cancer is among the most deadly diseases known, with 13 million new cancer cases and about 8 million casualties worldwide each year. This chapter introduces the current status and causes of cancer, and the characteristics of cancer tissues including abnormal metabolism, abnormal vasculature, resistance to anti-proliferative growth factors (GFs), unlimited replicative potential, immune system activation and inflammation, and interstitial pressure.
Keywords
- Vascular Endothelial Growth Factor
- Interstitial Pressure
- Immune System Activation
- Lung Cancer Death
- Pericyte Cover
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bergers G, Benjamin LE (2003) Angiogenesis: tumourigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257
Coppedè F, Lopomo A, Spisni R, Migliore L (2014) Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 20:943–956
De la Rica R, Aili D, Stevens MM (2012) Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev 64:967–978
Dinarello CA (2000) Proinflammatory cytokines. Chest 118:503–508
Dudley AC (2012) Tumor endothelial cells. Cold Spring Harb Perspect Med 2:a006536
Dvorak HF (2003) How tumors make bad blood vessels and stroma. Am J Pathol 162:1747–1757
Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev 63:136–151
Ganapathy-Kanniappan S, Geschwind JFH (2013) Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 12:152
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis. Nat Rev Cancer 4:891–899
Goldberg JE, Schwertfeger KL (2010) Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11:1133–1146
Gupta MK, Qin RY (2003) Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9:1144–1155
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–679
Hesketh R (2013) Introduction in cancer biology: a concise journey from epidemiology through cell and molecular biology to treatment and prospects. Cambridge University Press, New York
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Dalton WS (2008) Proteomic contributions to personalized cancer care. Mol Cell Proteomics 7:1780–1794
Koontongkaew S (2013) The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 4:66–83
Maeda H, Wua J, Sawaa T, Matsumurab Y, Horic K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392
Michener CM, Ardekani AM, Petricoin EF, Liotta LA, Kohn EC (2002) Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 26:249–255
Munn LL (2003) Aberrant vascular architecture in tumours and its importance in drug-based therapies. Drug Discov Today 8:396–403
Narang AS, Varia S (2011) Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 63:640–658
Ng JMK, Yu J (2015) Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci 16:2472–2496
Shuker DEG (2007) Socioeconomic and molecular basis of cancer. In: Missailidis S (ed) The cancer clock. Wiley, Chichester, pp 3–24
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64:9–29
Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37:63–74
Spencer DS, Puranik AS, Peppas NA (2015) Intelligent nanoparticles for advanced drug delivery in cancer treatment. Curr Opin Chem Eng 7:84–92
Stubbs JM, McSheehy PM, Griffiths JR, Bashford CL (2000) Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 6:15–19
Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–135
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033
Wakefield LM, Yang Y, Dukhanina O (2000) Transforming growth factor-β and breast cancer: lessons learned from genetically altered mouse models. Breast Cancer Res 2:100–106
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2017 The Author(s)
About this chapter
Cite this chapter
Feng, T., Zhao, Y. (2017). Current Status and Characteristics of Cancer. In: Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy. SpringerBriefs in Applied Sciences and Technology(). Springer, Singapore. https://doi.org/10.1007/978-981-10-3299-8_1
Download citation
DOI: https://doi.org/10.1007/978-981-10-3299-8_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-3297-4
Online ISBN: 978-981-10-3299-8
eBook Packages: EngineeringEngineering (R0)